Epperly Melissa B, — SEC Form 4 filings
SEC reporting owner CIK 1807359. 25 Form 4 filings on record with FilingPulse; latest filed 2026-09-18.
Transaction summary — filings shown
Covers all 25 filings on record, filed 2024-01-23 to 2026-09-18. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 7 legs across 5 filings — 75,791 shares, $2,136,530 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 34.
- Largest priced transaction: sale of 41,861 shares @ $28.68 ($1,200,573) in Roivant Sciences Ltd., filed 2026-03-18.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Roivant Sciences Ltd. (ROIV) | Director | 19 | — | 5 legs · 64,549 sh · $2,007,055 | 25 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | Chief Financial Officer | 2 | — | 2 legs · 11,242 sh · $129,475 | 2 |
| Kinnate Biopharma Inc. (KNTE) | Director | 1 | — | — | 4 |
| Nautilus Biotechnology, Inc. (NAUT) | Director | 3 | — | — | 3 |
Form 4 filings — Epperly Melissa B,
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-18 | 4 | Roivant Sciences Ltd. (ROIV) | Grant/award (A): 5,054 @ $0 · Grant/award (A): 10,531 (derivative) @ $0 | EDGAR |
| 2026-09-17 | 4 | Roivant Sciences Ltd. (ROIV) | Sale (S): 4,338 @ $39.65 · Sale (S): 600 @ $40.38 | EDGAR |
| 2026-09-14 | 4 | Roivant Sciences Ltd. (ROIV) | Tax withholding (F): 2,179 @ $40.94 | EDGAR |
| 2026-07-21 | 4 | Roivant Sciences Ltd. (ROIV) | Grant/award (A): 543 @ $0 | EDGAR |
| 2026-07-01 | 4 | Roivant Sciences Ltd. (ROIV) | Option exercise (M): 17,750 @ $4.46 · Sale (S): 15,002 @ $34.32 · Sale (S): 2,748 @ $34.71 · Option exercise (M): 17,750 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | Nautilus Biotechnology, Inc. (NAUT) | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2026-04-21 | 4 | Roivant Sciences Ltd. (ROIV) | Grant/award (A): 670 @ $0 | EDGAR |
| 2026-03-18 | 4 | Roivant Sciences Ltd. (ROIV) | Sale (S): 41,861 @ $28.68 | EDGAR |
| 2026-01-22 | 4 | Roivant Sciences Ltd. (ROIV) | Grant/award (A): 815 @ $0 · Tax withholding (F): 54 @ $22.98 | EDGAR |
| 2025-10-22 | 4 | Roivant Sciences Ltd. (ROIV) | Grant/award (A): 1,056 @ $0 | EDGAR |
| 2025-09-12 | 4 | Roivant Sciences Ltd. (ROIV) | Grant/award (A): 14,524 @ $0 · Other (J): 1,661 @ $13.77 · Grant/award (A): 33,726 (derivative) @ $0 | EDGAR |
| 2025-07-21 | 4 | Roivant Sciences Ltd. (ROIV) | Grant/award (A): 1,609 @ $0 | EDGAR |
| 2025-06-25 | 4 | Nautilus Biotechnology, Inc. (NAUT) | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2025-04-21 | 4 | Roivant Sciences Ltd. (ROIV) | Grant/award (A): 1,847 @ $0 | EDGAR |
| 2025-01-27 | 4 | Roivant Sciences Ltd. (ROIV) | Grant/award (A): 1,672 @ $0 · Tax withholding (F): 180 @ $11.21 | EDGAR |
| 2024-10-23 | 4 | Roivant Sciences Ltd. (ROIV) | Grant/award (A): 1,613 @ $0 | EDGAR |
| 2024-09-16 | 4 | Roivant Sciences Ltd. (ROIV) | Other (J): 4,245 @ $12.12 | EDGAR |
| 2024-09-12 | 4 | Roivant Sciences Ltd. (ROIV) | Grant/award (A): 16,406 @ $0 · Grant/award (A): 27,894 (derivative) @ $0 | EDGAR |
| 2024-07-25 | 4 | Roivant Sciences Ltd. (ROIV) | Grant/award (A): 1,702 @ $0 | EDGAR |
| 2024-06-17 | 4 | Nautilus Biotechnology, Inc. (NAUT) | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2024-04-26 | 4 | Roivant Sciences Ltd. (ROIV) | Grant/award (A): 1,146 @ $0 · Tax withholding (F): 123 @ $10.90 | EDGAR |
| 2024-04-05 | 4 | Kinnate Biopharma Inc. (KNTE) | Disposition to issuer (D): 60,751 (derivative) · Disposition to issuer (D): 20,250 (derivative) · Disposition to issuer (D): 25,000 (derivative) · Disposition to issuer (D): 20,250 (derivative) | EDGAR |
| 2024-02-12 | 4 | Zentalis Pharmaceuticals, Inc. (ZNTL) | Sale (S): 2,573 @ $11.44 | EDGAR |
| 2024-02-05 | 4 | Zentalis Pharmaceuticals, Inc. (ZNTL) | Grant/award (A): 75,000 @ $0 · Sale (S): 8,669 @ $11.54 · Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2024-01-23 | 4 | Roivant Sciences Ltd. (ROIV) | Grant/award (A): 1,207 @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1807359 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →